NCT00960557View on ClinicalTrials.gov

Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
Neoplasm Metastasis
Interventions
DRUG

Combretastatin A1 Diphosphate (OXi4503)

OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.

Trial Locations (4)

2145

OXiGENE Investigational Site, Westmead

3165

OXiGENE Investigational Site, Bentleigh

4101

OXiGENE Investigational Site, South Brisbane

5000

OXiGENE Investigational Site, Adelaide

Sponsors
All Listed Sponsors
lead

Mateon Therapeutics

INDUSTRY

NCT00960557 - Safety Study of Increasing Doses of Combretasatin A1 Diphosphate (OXi4503) as Monotherapy in Subjects With Hepatic Tumor Burden | Biotech Hunter | Biotech Hunter